Gapping down
In reaction to disappointing earnings/guidance: ARO -41.7%, (announces review of strategic alternatives), TITN -9%, TIF -1.6%
M&A news: TRP -4.1% (To acquire Columbia Pipeline (CPGX) for $25.50/share in cash, or ~$13 bln), PBA -3.2% (Pembina Pipeline to acquire certain sour natural gas processing assets from Paramount Resources for cash consideration of ~$556 mln & expects immediate earnings accretion, increases monthly dividend from $0.1525/share to $0.16/share ; announced C$300 mln bought deal financing; ~8.8 mln shares priced at C$34/share)
Other news: HTBX -35.8% (following 150%+ move higher on Thursday), CBAY -7.6% (CymaBay Therapeutics announces top-line results from its pilot Phase 2 clinical study of MBX-8025), CPS -3.5% (prices 6.62 mln common stock offering at $37.75/share for gross proceeds of $249.9 mln, upsized from 5.5 mln shares), REG -2.9% (prices offering of 3,100,000 shares of common stock at $75.25), NVS -1.8% (still checking), GSK -1.6% (still checking), DFT -0.9% (prices 6.62 mln common stock offering at $37.75/share for gross proceeds of $249.9 mln, upsized from 5.5 mln shares)
Analyst comments: PYPL -1.1% (downgraded to Hold from Buy at Stifel)